The Gross Law Firm Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV

Core Viewpoint - Cerevel Therapeutics Holdings, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its stock offering and the subsequent acquisition by AbbVie Inc. [1][3] Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes shareholders who sold or held shares during this timeframe [2]. - Shareholders are encouraged to register for the class action by June 3, 2025, to potentially be appointed as lead plaintiffs [4]. Group 2: Allegations Against Cerevel - The lawsuit claims that Cerevel's October 16, 2023, secondary stock offering omitted critical information about AbbVie's interest in acquiring the company at a significantly higher price than the offering price of $22.81 per share [3]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially low price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a profit exceeding $120 million when AbbVie announced the acquisition at $45 per share [3]. Group 3: Legal Representation - The Gross Law Firm is representing the shareholders in this class action, emphasizing its commitment to protecting investors' rights against deceitful business practices [5].